CLAIMS

1. A compound of ~~formula~~ Formula I:



Formula I

or a pharmaceutically acceptable salt, hydrate, polymorph, solvate, ~~prodrug~~, enantiomer, or stereoisomer thereof, wherein

~~Wherein:~~

R^1 ~~independently~~ represents halogen, -F, ~~H,~~ -Cl, ~~D or Br;~~

R^2 ~~independently~~ represents ~~H, D, or~~ 

;

R^3 ~~independently~~ represents ~~H, D,~~



 ,  ,  ,  ,

 ,  ,  ,

 ,  ,

 ,  ,  ,

 ,

 ,  ,

 ,  ,


or
 ;

R^4 ~~independently~~ represents



,


,


,


,


,


,


,


,


,


,


,


,


O
5
8
11
14
17
20

,


4
7
10
13
16
19
O

,


O
O
N
N
N
O
N

,


O
N

,


O
N
H
N

,


NH
NH
N
N
H
N
H

,


N
CH3
HO
OH
N
H

,


OH
HO
N
O
HO
OH


O
HN
NH
H
H
S
O

,

,


H
OH
HO
H
N
O
O

,



a is ~~independently~~ 2,3 or 7;

each b is independently 3, 5 or 6;

e is ~~independently~~ 1, 2 or 6; and

c and d are each independently H, D, -OH, -OD, C_1-C_6-alkyl, -NH_2 or -$COCH_3$.

2. A ~~Pharmaceutical~~ pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. Use of the ~~The~~ pharmaceutical composition of claim 2~~, which is formulated~~ to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup,

topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.

4. Use of compounds ~~Compounds~~ and compositions of claim 3 ~~are formulated~~ for the treatment of metabolic syndrome, hyperuricemia, gout, dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, and post prandial hyperglycemia.

5. The compound of claim 1, having the following structure:



.

6. A molecular conjugate of arhalofenate and compounds selected from a group consisting of R-Lipoic acid, eicosapentaenoic acid, docosahexaenoic acid, acetyl cysteine and salsalate.

~~5.~~7. The ~~A~~ molecular conjugate of claim 6, wherein the carboxylic acid compound is ~~arhalofenate and~~ R-Lipoic acid.

~~6.~~8. ~~A~~ The molecular conjugate of ~~arhalofenate and eicosapentaenoic acid~~ claim 6, wherein the carboxylic acid compound is eicosapentaenoic acid.

~~7.~~9. ~~A~~ The molecular conjugate of ~~arhalofenate and docosahexaenoic acid~~ claim 6, wherein the carbodylic acid compound is docosahexaenoic acid.

~~8.~~10. ~~A~~ The molecular conjugate of ~~arhalofenate and acetyl cysteine~~ claim 6, wherein the carboxylic acid compound is acetyl cysteine.

~~9.~~11. ~~A~~ The molecular conjugate of ~~arhalofenate and salsalate~~ claim 6, wherein the carboxylic acid compound is acetyl salsalate.